[go: up one dir, main page]

IS5260A - Dissolved sertraline formulations - Google Patents

Dissolved sertraline formulations

Info

Publication number
IS5260A
IS5260A IS5260A IS5260A IS5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A
Authority
IS
Iceland
Prior art keywords
formulations
dissolved sertraline
sertraline
dissolved
sertraline formulations
Prior art date
Application number
IS5260A
Other languages
Icelandic (is)
Inventor
Thomas Friesen Dwayne
Max Herbig Scott
Mysore Shanker Ravi
Blair West James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5260(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5260A publication Critical patent/IS5260A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS5260A 1997-07-01 1999-11-19 Dissolved sertraline formulations IS5260A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (1)

Publication Number Publication Date
IS5260A true IS5260A (en) 1999-11-19

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5260A IS5260A (en) 1997-07-01 1999-11-19 Dissolved sertraline formulations

Country Status (34)

Country Link
EP (1) EP0999829A1 (en)
JP (1) JP2000514100A (en)
KR (1) KR100366373B1 (en)
CN (1) CN1261794A (en)
AP (1) AP1192A (en)
AR (3) AR015917A1 (en)
AU (1) AU742535B2 (en)
BG (1) BG103918A (en)
BR (1) BR9810739A (en)
CA (1) CA2290974C (en)
CO (1) CO4940495A1 (en)
DZ (1) DZ2548A1 (en)
EA (1) EA002481B1 (en)
HN (1) HN1998000102A (en)
HR (1) HRP980377A2 (en)
HU (1) HUP0002236A3 (en)
ID (1) ID23429A (en)
IL (1) IL133076A (en)
IS (1) IS5260A (en)
MA (1) MA24587A1 (en)
NO (1) NO996520L (en)
OA (1) OA11243A (en)
PA (1) PA8454301A1 (en)
PE (1) PE97199A1 (en)
PL (1) PL337804A1 (en)
SK (1) SK181099A3 (en)
TN (1) TNSN98124A1 (en)
TR (1) TR199903297T2 (en)
TW (1) TW550087B (en)
UA (1) UA67741C2 (en)
UY (1) UY25071A1 (en)
WO (1) WO1999001120A1 (en)
YU (1) YU68299A (en)
ZA (1) ZA985708B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP2004507502A (en) 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク Sustained release formulation for growth hormone secretagogue
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
ES2439582T3 (en) * 2007-03-12 2014-01-23 Dsm Ip Assets B.V. Cosmetic compositions
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102711763A (en) * 2009-12-29 2012-10-03 兴和株式会社 Pharmaceutical composition for oral administration
EP2520299A1 (en) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Solid pharmaceutical composition for oral administration
CN109908354A (en) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 Sertraline hydrochloride takes orally concentrate and its preparation process
CN114894736B (en) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 A method for determining nitrate in chloride-type brine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (en) * 1989-08-30 1993-11-15 Pfizer USE OF SERTRALINE TO TREAT CHEMICAL ADDICTION.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
AR040279A2 (en) 2005-03-23
TNSN98124A1 (en) 2005-03-15
MA24587A1 (en) 1998-12-31
HUP0002236A3 (en) 2003-12-29
ZA985708B (en) 2000-01-10
KR100366373B1 (en) 2003-01-14
CA2290974A1 (en) 1999-01-14
CO4940495A1 (en) 2000-07-24
CN1261794A (en) 2000-08-02
SK181099A3 (en) 2000-07-11
DZ2548A1 (en) 2003-02-08
IL133076A (en) 2003-12-10
HRP980377A2 (en) 1999-04-30
TR199903297T2 (en) 2000-07-21
PE97199A1 (en) 1999-10-05
JP2000514100A (en) 2000-10-24
PA8454301A1 (en) 2000-09-29
TW550087B (en) 2003-09-01
HN1998000102A (en) 1999-01-08
EA199900962A1 (en) 2000-08-28
EA002481B1 (en) 2002-06-27
EP0999829A1 (en) 2000-05-17
KR20010013365A (en) 2001-02-26
CA2290974C (en) 2004-04-27
AR040280A2 (en) 2005-03-23
AU7544898A (en) 1999-01-25
AU742535B2 (en) 2002-01-03
NO996520D0 (en) 1999-12-28
NO996520L (en) 2000-02-29
WO1999001120A1 (en) 1999-01-14
BR9810739A (en) 2000-09-12
HUP0002236A2 (en) 2003-08-28
AR015917A1 (en) 2001-05-30
UY25071A1 (en) 2000-12-29
PL337804A1 (en) 2000-09-11
IL133076A0 (en) 2001-03-19
BG103918A (en) 2000-07-31
UA67741C2 (en) 2004-07-15
ID23429A (en) 2000-04-20
OA11243A (en) 2003-07-24
AP9801280A0 (en) 1998-06-30
AP1192A (en) 2003-07-23
YU68299A (en) 2002-06-19

Similar Documents

Publication Publication Date Title
MA24473A1 (en) FORMULATIONS
IS5555A (en) Selekoxib formulations
ID30031A (en) AGROKIMIA FORMULATIONS
ID23546A (en) ZIPRASIDON FORMULATIONS
NO20004240D0 (en) formulations
ATE224703T1 (en) EFFORTABLE FORMULATIONS
PT1130966E (en) ANTIPARASITARY FORMULATIONS
DE59802860D1 (en) DISINFECTANT
ID25533A (en) 2-METHYL-TIENO-BENZODIAZEPIN FORMULATION
DK0853945T3 (en) Liquid gonadotropin-containing formulations
ID23299A (en) PHARMACEUTICAL FORMULATIONS
DE69828330D1 (en) Activated Protein C Formulations
DK1109449T3 (en) Microcapsule formulations
DE69812475T2 (en) Photoresist composition
NO980546D0 (en) Pharmaceutical agents
DE69809717D1 (en) CONCENTRATED DISINFECTANTS
CY2006006I1 (en) PROTEIN FORMULATIONS
DE69935609D1 (en) FORMULATIONS CONTAINING CEFUROXIM-AXETIL
ATE232683T1 (en) MICROCAPSULE FORMULATIONS
DE69800779D1 (en) Photopolymerizable composition
DE69809633D1 (en) Photoresist composition
NO995147D0 (en) contrast agents
ID16781A (en) PHARMACEUTICAL FORMULATIONS
IS5260A (en) Dissolved sertraline formulations
NO20002590D0 (en) Formulations comprising dissolved paroxetine